申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US04632934A1
公开(公告)日:1986-12-30
The imidazole derivatives of the formula: ##STR1## wherein R is a hydrogen atom or an alkyl group, A.sub.1 and A.sub.2, which may be the same or different, each is an alkylene or an alkylene group, m is 0 or 1, and Z is ##STR2## wherein R.sub.1 and R.sub.2, which may be the same or different, each is a hydrogen atom or an alkyl group, and the terminal carbon atom bonded to the hetero atom of Z may be bonded to either A.sub.1 or A.sub.2 or COOR group (in the case of m being 0); and the pharmaceutically acceptable salts thereof. These compounds have a strong inhibitory effect on thromboxane synthetase from human or bovine platelet microsomes, and are useful as therapeutically actives for inflammation, hypertension, thrombus, cerebral apoplexy and asthma.
公式为:##STR1## 其中 R 是氢原子或烷基,A.sub.1 和 A.sub.2,可以相同也可以不同,每个都是烷基或烷基,m 为 0 或 1,Z 为 ##STR2## 其中 R.sub.1 和 R.sub.2,可以相同也可以不同,每个都是氢原子或烷基,Z 的杂原子所连接的末端碳原子可以连接到 A.sub.1 或 A.sub.2 或 COOR 域(当 m 为 0 时);以及其药学上可接受的盐。这些化合物对人类或牛血小板微粒体中的血栓素合酶具有强烈的抑制作用,并可用作治疗炎症、高血压、血栓、脑卒中和哮喘的治疗活性物质。